BioSpace1d
Regenxbio Gears Up to Challenge Sarepta in DMD as Gene Therapy Advances to Pivotal Studies
Regenxbio is pushing its Duchenne muscular dystrophy gene therapy into pivotal development, with a BLA planned for ...
RegenXBio’s RGX-202: Promising DMD Therapy with Best-in-Class Potential and Strategic BLA Plans
Bank of America Securities analyst Alec Stranahan maintained a Buy rating on RegenXBio (RGNX – Research Report) yesterday and set a price ...
FierceBiotech1d
After seeing improved muscle function in phase 1/2 trial, Regenxbio launches pivotal DMD study
Regenxbio’s investigational gene therapy improved muscle function for patients with Duchenne muscular dystrophy (DMD) in a phase 1/2 study. | Regenxbio’s investigational gene therapy improved muscle ...
BioSpace1h
RFK Jr.’s HHS Nomination, Biogen’s Lupus Win and Leqembi Struggles, Neurogene’s Rough Month, More
Trump fingers Robert F. Kennedy Jr. to lead the HHS, lupus and ATTR-CM dominate headlines this week, bluebird bio has a cash gap to leap and RegenxBio eyes Sarepta in Duchenne muscular dystrophy.
REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA
REGENXBIO Inc. (Nasdaq: RGNX) today announced that AFFINITY DUCHENNE®, the multi-center, open-label trial of RGX-202, a ...
ENDPOINTS NEWS1d
Re­genxbio shares first da­ta show­ing Duchenne gene ther­a­py im­proves mus­cle func­tion
Regenxbio reported improved muscle function in boys with Duchenne muscular dystrophy using their gene therapy RGX-202. The ...
What's Going On With REGENXBIO Shares Monday?
REGENXBIO stock is trading higher on Monday after the company reached a critical point in its trial for Duchenne gene therapy.
RegenXBio’s Promising Gene Therapy Advancements and Strategic Financial Growth: A Buy Recommendation
Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on RegenXBio (RGNX – Research Report) and increased the price target to ...
Investing7d
REGENXBIO's SWOT analysis: gene therapy stock poised for growth amid challenges
With a diverse pipeline targeting high-value indications such as Duchenne muscular dystrophy (DMD) and wet age-related macular degeneration (wet AMD (NASDAQ:AMD)), REGENXBIO has positioned itself as ...